The effectiveness of atorvastatin for the prevention of deep vein thrombosis in cancer patients undergoing chemotherapy

Table 2 Study efficacy end points

Efficacy endpoints	Atorvastatin N = 42	Rivaroxaban N = 44	p	OR;95% CI
Primary efficacy end points
Yes	1 (2.3%)	1 (2.2%)	1.000*	0.953; 0.240–3.971
No	41 (97.7%)	43 (97.8%)	1.000*	0.953; 0.240–3.971
Secondary efficacy end points
Yes	17 (40.5%)	12 (27.3%)	0.286^†	1.337; 0.875–2.042
No	25 (59.5%)	32 (72.7%)	0.286^†	1.337; 0.875–2.042

ISSN: 1477-9560